Lucisot (Sotorasib) 120 mg

Indicated for the treatment of adult patients with KRAS G12C-mutated Non-Small Cell Lung Cancer (NSCLC) who have received at least one prior systemic therapy.

⚠️ Requirement: Presence of KRAS G12C mutation must be confirmed by an FDA-approved test.

Standard Dosage: 960 mg once daily.

⚠️ PILL COUNT AWARENESS:

• Take 8 tablets (120 mg each) once daily at the same time.
• One bottle (56 tabs) lasts exactly 7 days.

💊 Administration:

• Swallow tablets whole. Do not chew, crush, or split.
• Can be taken with or without food.
• Avoid Proton Pump Inhibitors (PPIs) and H2 blockers (antacids), as they reduce the drug's absorption.

• Hypersensitivity to Sotorasib.
• Pregnancy and breastfeeding (potential harm to fetus).
• Severe hepatic impairment.

Common side effects requiring monitoring:

• Hepatotoxicity: Elevated liver enzymes (ALT/AST). Frequent blood tests are necessary.
• Gastrointestinal: Diarrhea, nausea.
• Musculoskeletal pain: Joint or muscle aches.
• Lungs: Cough or dyspnea (monitor for Interstitial Lung Disease).